Wisdom Bioscience Forms Scientific Advisory Board to Drive Innovation in Non-Invasive Oral Cancer Diagnostics
Wisdom Bioscience, Inc., an emerging biotechnology company dedicated to transforming the detection and screening of oral cancer, has officially announced the formation of its Scientific Advisory Board (SAB) following the successful close of its initial funding round. The establishment of the SAB marks a significant milestone in the company’s mission to advance non-invasive, genomic-based oral cancer diagnostics, integrating cutting-edge science with practical clinical applications.
The newly formed SAB brings together a distinguished panel of experts across molecular diagnostics, oncology screening, and cell-free DNA (cfDNA) research, ensuring that Wisdom Bioscience benefits from unparalleled scientific and strategic guidance. The board includes Drs. Giulia Kennedy, Arnold Levine, John Sninsky, Martin Goldberg, and Professor Tin Tin Su, each of whom possesses extensive expertise in research, development, and commercialization of diagnostic and therapeutic innovations.
Dr. Giulia Kennedy, Ph.D., co-founder and Chief Scientific Officer of PinkDx, Inc., is renowned for her work in molecular diagnostics focused on women’s gynecological cancers. Before PinkDx, she held dual leadership roles as Chief Scientific Officer and Chief Medical Officer at Veracyte, Inc., where she led the development and commercialization of eight genomic diagnostic tests that reshaped patient care standards. Her experience brings invaluable insight into the translation of genomic technologies into routine clinical practice.
Arnold Levine, Ph.D., has devoted more than three decades to molecular oncology and genomics, with a particular focus on tumor suppressor genes, cancer therapies, and the immune response to malignancies. His research spans epidemiology, cancer prevention, and therapeutic innovation, positioning him as a thought leader in integrating scientific discovery with practical clinical applications.
John Sninsky, Ph.D., brings extensive experience in leading laboratory-developed test and in vitro diagnostic organizations, including both startups and large enterprises. His contributions to PCR, next-generation sequencing (NGS), liquid biopsies, and genome-wide association studies have helped bridge the gap between cutting-edge research and reimbursed clinical practice, particularly in oncology and infectious disease diagnostics.
Martin Goldberg, Ph.D., Distinguished Scientific Fellow at Seer, Inc., has spent over 30 years navigating the life sciences tools industry, with a focus on genomics and proteomics platforms. He is particularly skilled at guiding early-stage companies through technical, tactical, and strategic challenges, ensuring their innovations reach both research and clinical markets effectively.
Professor Tin Tin Su, Ph.D., brings more than 25 years of expertise in chemical genetics and tissue regeneration after radiation damage, utilizing both Drosophila and human cancer models to explore novel therapeutic and diagnostic approaches.
Founded in 2024, Wisdom Bioscience is pioneering the integration of advanced genomic technologies into routine dental care to enable early, non-invasive detection of oral cancer. Its platform leverages a simple mouth swab combined with next-generation sequencing technology to detect oral cancer at earlier stages, with the goal of making oral cancer screening a standard component of dental appointments.
The company is supported by a distinguished group of investors, including Stephen Quake and Jay Flatley, reflecting strong market confidence in Wisdom Bioscience’s vision and technology. Funds from the initial financing will accelerate clinical validation and prepare the company for a commercial launch later this year, underscoring its commitment to improving oral cancer outcomes through innovation, accessibility, and early detection.
“The formation of our Scientific Advisory Board, coupled with support from highly respected investors, is a strong endorsement of our vision,” said a company spokesperson. “It positions us to advance our product pipeline strategically while expanding our service offerings, ultimately bringing transformative change to oral cancer diagnostics and patient care.”
With this newly established SAB and a robust scientific and financial foundation, Wisdom Bioscience is poised to redefine how oral cancer is detected, offering hope for earlier intervention and improved patient outcomes worldwide.
